• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Docs resist prostate test recommendation | MassDevice.com On Call

Docs resist prostate test recommendation | MassDevice.com On Call

May 29, 2012 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL — Primary care docs surveyed by Johns Hopkins University researchers say they’re unlikely to curtail their use of a test to detect prostate cancer, despite recommendations from the U.S. Preventive Services Task Force.

The USPSTF stirred up a controversy last year when it suggested that routine prostate-specific antigen tests for healthy men might do more harm than good.

The task force reiterated its guidance last week, igniting a furious response from urologists and kudos from other quarters.

Now a small Johns Hopkins poll of 125 PC docs shows that although they agree with cutting back on screening for men over age 75 and for those not expected to live more than 10 years, most are not expecting to stop giving the test to younger, healthier patients.

Nearly 75% said their patients expect to receive PSA tests and 66% said it’s quicker to perform the test than to explain the reasons for discontinuing it. More than half said they fear exposure to malpractice lawsuits if they fail to order the tests.

"It can be very difficult for doctors to break down the belief that all cancer screening tests are invariably good for all people, all the time," study leader Dr. Craig Pollack said in prepared remarks. "Everyone agrees that PSA screening isn’t as good as we want it to be. If we had a test that was a slam dunk, it would be different. But now we know that for many men, the benefits may be small and the harms significant."

Clinical results seem to back the USPTF recommendations. Early results presented at the European Assn. of Urology this month from a long-term study of prostate cancer patients support the USPSTF’s decision, suggesting that surgical prostatectomy barely increased the likelihood for survival in patients with low-risk tumors.

 Wireless glucometer makers throw down in San Diego
A trio of wireless diabetes device companies – Glooko, AgaMatrix, and Telcare – threw down during a panel at an mHealth conference in San Diego last week, when Telcare CEO Jonathon Javitt came out swinging.
Read more

 Doc groups look to the House for healthcare reform
The system Medicare uses to pay doctors needs a serious overhaul and a clutch of high-profile physician associations want some of the innovative payment systems mandated by the healthcare law to stay in place, the groups told the U.S. House of Representatives last week.
Read more

 A minimally-invasive device for heartburn surgery
The Wall Street Journal is highlighting an alternative to traditional laparoscopic heartburn surgery: The Esophyx device made by EndoGastric Solutions of Redwood City, Calif.
Read more

 Can Big Data improve healthcare in just 1 day?
The Health 2.0 Boston Code-a-thon gave participants 1 day to create an application to transform large amounts of healthcare data into useful information for patients and care providers. The winner, a website called No Sleep Kills, provides access to data linking poor sleeping patterns, drowsy drivers and auto accidents.
Read more

Filed Under: Big Data, Diagnostics, Endoscopic, Healthcare Reform, News Well Tagged With: AgaMatrix Inc., endogastricsolutions, Glooko, On Call, Prostate, Telcare Inc., U.S. Preventive Services Task Force (USPSTF)

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy